Ironwood Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Ironwood Pharmaceuticals şirketinin kazançları yıllık ortalama -45.8% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.3% oranında artan oldu. Gelirler yıllık ortalama 0.5% oranında azalan oldu.

Anahtar bilgiler

-45.8%

Kazanç büyüme oranı

-46.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	-0.5%
Özkaynak getirisi	n/a
Net Marj	-0.7%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Aug 16

Recent updates

Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S

Oct 24

Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Aug 16

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Jun 27

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Jun 20

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 16

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Jan 31

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Dec 19

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Jul 25

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Apr 18

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Mar 28

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

Oct 05

These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Sep 28

Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

Jul 29

Gelir ve Gider Dağılımı

Ironwood Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:IRWD Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	378	-2	158
30 Jun 24	401	9	153
31 Mar 24	414	-1,052	149
31 Dec 23	443	-1,002	142
30 Sep 23	432	-952	124
30 Jun 23	427	-917	120
31 Mar 23	417	182	118
31 Dec 22	411	175	116
30 Sep 22	421	168	116
30 Jun 22	416	173	115
31 Mar 22	422	527	112
31 Dec 21	414	528	111
30 Sep 21	413	530	116
30 Jun 21	413	509	123
31 Mar 21	398	143	131
31 Dec 20	390	106	140
30 Sep 20	399	111	144
30 Jun 20	427	97	150
31 Mar 20	440	84	158
31 Dec 19	428	59	170
30 Sep 19	433	19	180
30 Jun 19	367	-153	189
31 Mar 19	346	-173	207
31 Dec 18	347	-194	217
30 Sep 18	310	-190	227
30 Jun 18	331	-71	238
31 Mar 18	315	-108	237
31 Dec 17	298	-55	230
30 Sep 17	292	-143	229
30 Jun 17	271	-143	212
31 Mar 17	260	-121	191
31 Dec 16	274	-82	173
30 Sep 16	240	-82	150
30 Jun 16	213	-96	135
31 Mar 16	187	-123	131
31 Dec 15	150	-143	125
30 Sep 15	134	-166	124
30 Jun 15	112	-161	122
31 Mar 15	91	-173	119
31 Dec 14	76	-190	117
30 Sep 14	43	-204	115
30 Jun 14	31	-224	117
31 Mar 14	34	-229	119
31 Dec 13	23	-273	123

Kaliteli Kazançlar: IRWD şu anda kârlı değil.

Büyüyen Kar Marjı: IRWD şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: IRWD kârlı değildir ve zararlar son 5 yılda yılda 45.8% oranında artmıştır.

Büyüme Hızlandırma: IRWD 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: IRWD kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: IRWD 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Ironwood Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings: EPS misses analyst expectations

Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

First quarter 2024 earnings released: US$0.03 loss per share (vs US$0.30 profit in 1Q 2023)

Full year 2023 earnings: EPS misses analyst expectations

Third quarter 2023 earnings: EPS misses analyst expectations

Recent updates

Third quarter 2024 earnings: EPS misses analyst expectations

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Full Year 2024

Price target increased by 11% to US$12.67

Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S

Consensus EPS estimates fall by 50%

Investor sentiment deteriorates as stock falls 20%

Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 13% to US$14.17

New minor risk - Share price stability

Ironwood Pharmaceuticals, Inc. Revises Earnings Guidance for Its Fiscal Year 2024

Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) dropped from Russell 2000 Growth-Defensive Index

Insufficient new directors

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Independent Chairman of the Board notifies of intention to sell stock

Independent Director recently sold US$518k worth of stock

Independent Director notifies of intention to sell stock

CEO & Director recently sold US$436k worth of stock

CEO & Director notifies of intention to sell stock

Price target decreased by 9.3% to US$16.33

Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024

First quarter 2024 earnings released: US$0.03 loss per share (vs US$0.30 profit in 1Q 2023)

Ironwood Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

Price target decreased by 10% to US$18.50

New minor risk - Share price stability

New minor risk - Insider selling

Full year 2023 earnings: EPS misses analyst expectations

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2024

CEO & Director notifies of intention to sell stock

Price target increased by 11% to US$19.83

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Fiscal Year 2023 and Provides Earnings Guidance for the Fiscal Year 2024

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Consensus EPS estimates fall by 42%

Ironwood Pharmaceuticals, Inc. provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Ironwood Pharmaceuticals, Inc. Provids Earnings Guidance for the Year 2023

Ironwood Pharmaceuticals, Inc. Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

Ironwood Pharmaceuticals, Inc. Presents Positive Final Data from Stars Nutrition, A Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Price target increased by 15% to US$16.50

Senior VP recently bought US$300k worth of stock

Ironwood Pharmaceuticals, Inc. Revises Financial Guidance for the Year 2023

New major risk - Negative shareholders equity

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old

CEO & Director notifies of intention to sell stock

CEO & Director recently sold US$364k worth of stock

Price target increased by 12% to US$14.33

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Ironwood Pharmaceuticals, Inc. Presents Results from Phase III Clinical Trial in Pediatric Patients

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

CEO & Director notifies of intention to sell stock

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Senior VP & COO recently sold US$388k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for 2023